---
title: "PROCEPT BioRobotics Corporation (PRCT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PRCT.US.md"
symbol: "PRCT.US"
name: "PROCEPT BioRobotics Corporation"
industry: "Health Care Equipment"
datetime: "2026-05-21T16:49:22.361Z"
locales:
  - [en](https://longbridge.com/en/quote/PRCT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PRCT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PRCT.US.md)
---

# PROCEPT BioRobotics Corporation (PRCT.US)

## Company Overview

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.procept-biorobotics.com](https://www.procept-biorobotics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: C (0.41)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 60 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 29.26% |  |
| Net Profit YoY | -13.62% |  |
| P/B Ratio | 4.60 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1599988704.84 |  |
| Revenue | 322024000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -27.81% | E |
| Profit Margin | -31.82% | E |
| Gross Margin | 64.89% | A |
| Revenue YoY | 29.26% | A |
| Net Profit YoY | -13.62% | D |
| Total Assets YoY | -6.22% | D |
| Net Assets YoY | -10.66% | D |
| Cash Flow Margin | 68.44% | C |
| OCF YoY | 29.26% | A |
| Turnover | 0.64 | B |
| Gearing Ratio | 28.62% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - PROCEPT BioRobotics Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "29.26%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.62%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.60",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1599988704.84",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "322024000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-27.81%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-31.82%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "64.89%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "29.26%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.62%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.22%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-10.66%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "68.44%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "29.26%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.64",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "28.62%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -15.61 | 153/183 | - | - | - |
| PB | 4.60 | 95/183 | 7.05 | 4.88 | 4.09 |
| PS (TTM) | 4.97 | 92/183 | 11.02 | 6.38 | 4.83 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 50% |
| Overweight | 1 | 8% |
| Hold | 4 | 33% |
| Underweight | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 28.61 |
| Highest Target | 37.00 |
| Lowest Target | 20.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PRCT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PRCT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PRCT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PRCT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**